BURLINGTON, Mass.--(BUSINESS WIRE)--AlloCure, Inc., a clinical stage biotechnology company focused on the treatment of kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AC607, the company’s investigational treatment for acute kidney injury (AKI).
